Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Regulatory
51 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Ziftomenib | US FDA | Acute Myeloid Leukemia | KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 ) | approved | Nov 13, 2025 | openfda |
Data updated 13 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Sorafenib | 38 | 22 | 16 |
| Sunitinib | 33 | 31 | 2 |
| Midostaurin | 25 | 21 | 3 |
| Quizartinib | 21 | 13 | 7 |
| Gilteritinib | 20 | 17 | 3 |
| Ponatinib | 16 | 12 | 4 |
| Lestaurtinib | 14 | 13 | 1 |
| Tretinoin | 13 | 7 | 6 |
| Crenolanib | 11 | 10 | 1 |
| Ivosidenib | 11 | 11 | 0 |
| Pexidartinib | 10 | 2 | 8 |
| Daunorubicin | 6 | 3 | 3 |
| Venetoclax |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 5 |
| 4 |
| 1 |
| Arsenic Trioxide | 4 | 1 | 3 |
| Cytarabine | 4 | 2 | 2 |
| Enasidenib | 4 | 4 | 0 |
| FLT3 Tyrosine Kinase Inhibitor TTT-3002 | 4 | 4 | 0 |
| Linifanib | 4 | 4 | 0 |
| Olutasidenib | 4 | 4 | 0 |
| Palbociclib | 4 | 4 | 0 |
| AG1295 | 3 | 3 | 0 |
| Azacitidine | 3 | 3 | 0 |
| Chemotherapy | 3 | 1 | 2 |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | 3 | 1 | 2 |
| KW2449 | 3 | 3 | 0 |
| Nilotinib | 3 | 3 | 0 |
| Olaparib | 3 | 3 | 0 |
| R406 | 3 | 3 | 0 |
| Revumenib | 3 | 3 | 0 |
| SU5614 | 3 | 0 | 3 |
| AGS324 | 2 | 2 | 0 |
| Anti-CD33 | 2 | 2 | 0 |
| Dasatinib | 2 | 2 | 0 |
| FLT3 Inhibitor FF-10101 Succinate | 2 | 2 | 0 |
| Hematopoietic Cell Transplantation | 2 | 2 | 0 |
| Imatinib | 2 | 1 | 1 |
| Imatinib Mesylate | 2 | 1 | 1 |
| NSC348884 | 2 | 2 | 0 |
| Selumetinib | 2 | 1 | 1 |
| Tandutinib | 2 | 1 | 1 |
| Tyrphostin AG 1296 | 2 | 2 | 0 |
| Ziftomenib | 2 | 2 | 0 |
| 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine | 1 | 1 | 0 |
| Anthracycline Antineoplastic Antibiotic | 1 | 0 | 1 |
| Anti-CD123 | 1 | 1 | 0 |
| AS602868 | 1 | 1 | 0 |
| BPTES | 1 | 1 | 0 |
| Decitabine | 1 | 1 | 0 |
| Entrectinib | 1 | 1 | 0 |
| Etoposide | 1 | 1 | 0 |
| Gemtuzumab Ozogamicin | 1 | 1 | 0 |
| GSK321 | 1 | 1 | 0 |
| Idarubicin | 1 | 1 | 0 |
| JQ-1 | 1 | 1 | 0 |
| K 252a | 1 | 0 | 1 |
| Larotrectinib | 1 | 1 | 0 |
| Ningetinib | 1 | 1 | 0 |
| OICR-9429 | 1 | 1 | 0 |
| Pacritinib | 1 | 1 | 0 |
| Selinexor | 1 | 0 | 1 |
| Tamibarotene | 1 | 0 | 1 |
| Tirbanibulin | 1 | 1 | 0 |
| Tyrphostin AG 1295 | 1 | 1 | 0 |
| Valproic Acid | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.